Inflammatory Myopathies: Evaluation and Management

ABSTRACT

The inflammatory myopathies, including dermatomyositis, inclusion body myositis, and polymyositis, are poorly understood autoimmune diseases affecting skeletal muscle. Dermatomyositis is a disease mainly of skin and muscle, but may affect lung and other tissues. Proximal or generalized weakness or skin rash are the typical presenting features. Inclusion body myositis has a specific clinical pattern of weakness that generally distinguishes it from other inflammatory myopathies, with prominent involvement of wrist and finger flexors, and quadriceps. Polymyositis generally presents with proximal or generalized weakness. Typical dermatomyositis muscle pathology is quite distinct, with perivascular inflammatory cells that include plasmacytoid dendritic cells, and abnormal capillaries and perimysial perifascicular myofibers. Both inclusion body myositis and polymyositis usually have infiltration into muscle of large numbers of inflammatory cells, typically surrounding and displacing, and sometimes invading, myofibers. Inclusion body myositis is refractory to corticosteroids and to several immunomodulating therapies that have been used. Dermatomyositis and polymyositis are treated with corticosteroids and a variety of agents. Osteoporosis and opportunistic infections pose a significant risk during treatment of patients. This review discusses the clinical manifestations, pathology, and treatment approaches for the inflammatory myopathies.

KEYWORDS

Dermatomyositis - inclusion body myositis - inflammatory myopathy - necrotizing myopathy - polymyositis

REFERENCES

• 1 Greenberg S A. Proposed immunologic models of the inflammatory myopathies and their potential therapeutic implications.  Neurology. 2007;  69 2008-2019
• 2 Shirani Z, Kucenic M J, Carroll C L et al.. Pruritus in adult dermatomyositis.  Clin Exp Dermatol. 2004;  29 273-276
• 3 Hundley J L, Carroll C L, Lang W et al.. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life.  J Am Acad Dermatol. 2006;  54 217-220
• 4 Kubis N, Woimant F, Polivka M et al.. A case of dermatomyositis and muscle sarcoidosis in a Caucasian patient.  J Neurol. 1998;  245 50-52
• 5 Hart Y, Schwartz M S, Bruckner F, McKeran R O. Relapsing dermatomyositis associated with sarcoidosis.  J Neurol Neurosurg Psychiatry. 1988;  51 311-313
• 6 Lipton J H, McLeod B D, Brownell A K. Dermatomyositis and granulomatous myopathy associated with sarcoidosis.  Can J Neurol Sci. 1988;  15 426-429
• 7 Brateanu A C, Caracioni A, Smith H R. Sarcoidosis and dermatomyositis in a patient with hemoglobin SC. A case report and literature review.  Sarcoidosis Vasc Diffuse Lung Dis. 2000;  17 190-193
• 8 Greenberg S A, Pinkus J L, Pinkus G S et al.. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.  Ann Neurol. 2005;  57 664-678
• 9 Yunis E J, Samaha F J. Inclusion body myositis.  Lab Invest. 1971;  25 240-248
• 10 Lotz B P, Engel A G, Nishino H et al.. Inclusion body myositis. Observations in 40 patients.  Brain. 1989;  112(Pt 3) 727-747
• 11 Badrising U A, Maat-Schieman M L, van Houwelingen J C et al.. Inclusion body myositis Clinical features and clinical course of the disease in 64 patients.  J Neurol. 2005;  252(12) 1448-1454
• 12 Badrising U A, Maat-Schieman M, van Duinen S G et al.. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.  Neurology. 2000;  55 1385-1387
• 13 Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients.  Clin Investig. 1993;  71 351-361
• 14 Lindberg C, Persson L I, Bjorkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases.  Acta Neurol Scand. 1994;  89 123-131
• 15 Sayers M E, Chou S M, Calabrese L H. Inclusion body myositis: analysis of 32 cases.  J Rheumatol. 1992;  19 1385-1389
• 16 Griggs R C, Askanas V, DiMauro S et al.. Inclusion body myositis and myopathies.  Ann Neurol. 1995;  38 705-713
• 17 van der Meulen M F, Hoogendijk J E, Moons K G et al.. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis.  Neuromuscul Disord. 2001;  11 447-451
• 18 Hoogendijk J E, Amato A A, Lecky B R et al.. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.  Neuromuscul Disord. 2004;  14 337-345
• 19 Amato A A, Griggs R C. Unicorns, dragons, polymyositis, and other mythological beasts.  Neurology. 2003;  61 288-289
• 20 van der Meulen M F, Bronner I M, Hoogendijk J E et al.. Polymyositis: an overdiagnosed entity.  Neurology. 2003;  61 316-321
• 21 Bohan A, Peter J B. Polymyositis and dermatomyositis (first of two parts).  N Engl J Med. 1975;  292 344-347
• 22 Miller F W, Rider L G, Plotz P H et al.. Diagnostic criteria for polymyositis and dermatomyositis.  Lancet. 2003;  362 1762-1763 , author reply 1763
• 23 Dalakas M C, Hohlfeld R. Polymyositis and dermatomyositis.  Lancet. 2003;  362 971-982
• 24 Krahn M, Lopez de Munain A, Streichenberger N et al.. CAPN3 mutations in patients with idiopathic eosinophilic myositis.  Ann Neurol. 2006;  59 905-911
• 25 Emslie-Smith A M, Engel A G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration.  Neurology. 1991;  41 936-939
• 26 De Bleecker J, Vervaet V, Van den Bergh P. Necrotizing myopathy with microvascular deposition of the complement membrane attack complex.  Clin Neuropathol. 2004;  23 76-79
• 27 Levin M I, Mozaffar T, Al-Lozi M T, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features.  Neurology. 1998;  50 764-767
• 28 Gibson S J, Lindh J M, Riter T R et al.. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.  Cell Immunol. 2002;  218 74-86
• 29 Bronner I M, Hoogendijk J E, Wintzen A R et al.. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy.  J Neurol. 2003;  250 480-485
• 30 Dimitri D, Andre C, Roucoules J et al.. Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology.  Muscle Nerve. 2007;  35 389-395
• 31 Hengstman G J, ter Laak H J, Vree Egberts W T et al.. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.  Ann Rheum Dis. 2006;  65 1635-1638
• 32 Muscle Study Group . Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body The MSG myositis.  Neurology. 2004;  63 718-720
• 33 Muscle Study Group . Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.  Neurology. 2001;  57 1566-1570
• 34 Dalakas M C, Sonies B, Dambrosia J et al.. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.  Neurology. 1997;  48 712-716
• 35 Dalakas M C, Koffman B, Fujii M et al.. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.  Neurology. 2001;  56 323-327
• 36 Badrising U A, Maat-Schieman M L, Ferrari M D et al.. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.  Ann Neurol. 2002;  51 369-372
• 37 Walter M C, Lochmuller H, Toepfer M et al.. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.  J Neurol. 2000;  247 22-28
• 38 Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.  Neurology. 2003;  61 260-262
• 39 Fisler R E, Liang M G, Fuhlbrigge R C et al.. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.  J Am Acad Dermatol. 2002;  47 505-511
• 40 Summey B T, Yosipovitch G. Glucocorticoid-induced bone loss in dermatologic patients: an update.  Arch Dermatol. 2006;  142 82-90
• 41 Saag K G, Emkey R, Schnitzer T J et al.. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.  N Engl J Med. 1998;  339 292-299
• 42 Wallach S, Cohen S, Reid D M et al.. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.  Calcif Tissue Int. 2000;  67 277-285
• 43 Rowin J, Amato A A, Deisher N et al.. Mycophenolate mofetil in dermatomyositis: is it safe?.  Neurology. 2006;  66 1245-1247
• 44 Viguier M, Fouéré S, de la Salmonière P et al.. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy.  Medicine (Baltimore). 2003;  82 82-86
• 45 Uchino M, Araki S, Yoshida O et al.. High single-dose alternate-day corticosteroid regimens in treatment of polymyositis.  J Neurol. 1985;  232 175-178
• 46 Fenichel G M, Mendell J R, Moxley III R T et al.. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy.  Arch Neurol. 1991;  48 575-579
• 47 Gluck O S, Murphy W A, Hahn T J, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy.  Arthritis Rheum. 1981;  24 892-898
• 48 Miller F W, Leitman S F, Cronin M et al.. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.  N Engl J Med. 1992;  326 1380-1384